The Cooper Companies Inc. (NYSE:COO) subsidiary CooperVision expanded the recall of its Avaira contact lenses to include some lots from its Avaira Sphere line.
The 6.6 million Avaira Sphere lenses affected by the recall contained excess silicone residue and failed to meet FDA quality requirements. The silicone residue can cause hazy vision, discomfort, severe eye pain or injuries requiring medical treatment.
CooperVision intends to replace the recalled lenses with untainted Avaira Sphere inventory.
"The company is confident we found the problem and have taken corrective action to fix the problem," Christine Moench, CooperVision’s vice president of global regulatory affairs & quality assurance in prepared remarks. "The health and safety of our customers is our top priority."
CooperVision launched a recall site today, where contact wearers can enter lens numbers to see if their lenses are impacted.
The Pleasanton, Calif.-based vision-care company issued the voluntary recall on its Avaira Toric contact lenses last month over reports of eye pain and corneal abrasion.
Within a week, the voluntary recall was bumped up to Class I status by the federal watchdog agency.
With news of the recall, COO’s stock dropped from a market opening of $65.06 per share to $53.20 per share yesterday.